Table of Contents
- Executive Summary: The 2025 Jet Injection Landscape
- Technology Overview: How Modern Jet Injectors Work
- Key Manufacturers and Innovators (2025 Update)
- Current Market Size, Segmentation & 2025 Valuations
- Growth Drivers: Patient Demand, Regulations, and Pharma Partnerships
- Emerging Applications: Beyond Vaccines and Insulin
- Competitive Analysis: Leading Players and Strategic Moves
- Regulatory and Safety Landscape: Approvals, Standards, and Challenges
- Market Forecasts: Growth Projections through 2030
- Future Outlook: Disruptive Technologies and Investment Hotspots
- Sources & References
Executive Summary: The 2025 Jet Injection Landscape
Jet injection technology for transdermal drug delivery is entering a phase of accelerated development and commercial adoption in 2025, driven by the growing demand for needle-free alternatives in both clinical and at-home settings. These systems use high-pressure streams to deliver medications through the skin, eliminating the need for traditional hypodermic needles. The technology offers advantages such as reduced pain, lower risk of needle-stick injuries, improved patient compliance, and enhanced suitability for mass vaccination or chronic disease management programs.
Key market players have made significant advancements in both device design and regulatory progress. PharmaJet has continued to expand the adoption of its needle-free injectors, notably with its Stratis and Tropis platforms, which have secured approvals for vaccine administration across various geographies. In 2024, PharmaJet announced new collaborations with global health organizations to support mass immunization campaigns, targeting diseases such as influenza, polio, and COVID-19, and is expected to extend its reach in 2025.
Similarly, Portal Instruments has advanced the development of its digitally controlled jet injection system, which enables precise and rapid subcutaneous delivery of biologics and large-molecule drugs. The company’s partnerships with major pharmaceutical manufacturers have progressed toward pivotal clinical trials and regulatory filings, with commercialization anticipated in the near term. In parallel, Inovio Pharmaceuticals continues to invest in its Cellectra device line, focusing on DNA medicines and vaccines, with ongoing trials for infectious disease and oncology indications.
The regulatory outlook is favorable, with jet injection devices gaining increasing recognition from agencies such as the U.S. FDA and the World Health Organization for their role in expanding access to essential medicines. Initiatives to phase out traditional needles in mass immunization settings are expected to accelerate the deployment of jet injectors, particularly in resource-limited regions. Furthermore, advances in device miniaturization and connectivity are enabling user-friendly, disposable, or reusable injectors for self-administration, a key trend as personalized medicine and at-home treatments proliferate.
Looking ahead, the jet injection landscape in 2025 and beyond is marked by expanding indications, broadening regulatory support, and entry into consumer health markets. Industry participants anticipate additional approvals for new drug-device combinations, growing adoption by public health agencies, and increased investment in next-generation, smart injector platforms. The convergence of these trends positions jet injection technology as a transformative modality in the global drug delivery ecosystem.
Technology Overview: How Modern Jet Injectors Work
Jet injection technology has evolved significantly, positioning itself as a promising alternative to traditional needle-based transdermal drug delivery. Modern jet injectors use high-velocity streams of liquid medication to penetrate the skin and deliver compounds to subcutaneous or intramuscular tissue without the use of needles. This approach addresses several challenges inherent to conventional injections, including needle phobia, risk of needlestick injuries, and cross-contamination concerns.
Contemporary jet injectors are typically powered by spring, gas, or electromagnetic mechanisms. These devices generate sufficient pressure—often exceeding 100 meters per second—to create a fine, high-speed liquid jet that breaches the stratum corneum without causing significant tissue trauma. The depth and dispersion of drug delivery can be precisely controlled by adjusting parameters such as pressure, nozzle diameter, and injection duration. In 2025, leading manufacturers continue to refine these parameters to optimize patient comfort and delivery efficiency.
A notable advancement is the shift from multi-use-nozzle jet injectors (now largely phased out due to safety concerns) to single-use, disposable nozzle designs. This development has been crucial in reducing the risk of cross-contamination and making jet injectors more suitable for mass immunization campaigns and home healthcare settings. For example, PharmaJet offers both intramuscular and intradermal jet injectors that utilize single-use syringes, which are FDA-cleared and CE marked for vaccine administration. Their technology is compatible with multiple vaccine formulations, including influenza and COVID-19 vaccines.
Further technological integration is visible in devices like the INJEX system, which employs a spring-powered mechanism to deliver medication subcutaneously, commonly used for insulin and local anesthetics. The design focuses on minimizing pain and maximizing convenience, particularly for chronic disease management.
Looking into the near future, manufacturers are exploring digital enhancements such as dose tracking and connectivity features for remote monitoring and adherence support. Companies like Crossject are developing prefilled, ready-to-use jet injectors for emergency drugs, aiming for regulatory approvals in key markets by 2026. Integration of smart capabilities is likely to become standard, improving the ease of use and safety profiles of next-generation jet injectors.
In summary, modern jet injection technology leverages precise mechanical and digital engineering to deliver drugs transdermally without needles, with ongoing improvements focused on safety, user experience, and digital integration expected to accelerate adoption in the coming years.
Key Manufacturers and Innovators (2025 Update)
The landscape of jet injection technology for transdermal drug delivery continues to evolve rapidly in 2025, driven by both established manufacturers and a new cohort of innovative startups. The sector’s growth is underpinned by increasing demand for needle-free solutions to improve patient compliance, reduce sharps waste, and address needle-phobia, especially in chronic care and vaccination programs.
Among the global leaders, Philips remains prominent with its Jet Injection System, which has undergone iterative refinements to enhance dosing precision and user ergonomics. In the United States, Crossject is advancing its ZENEO® portfolio, which features pre-filled, single-use needle-free injectors for emergency and routine drug administration. Notably, Crossject’s platform obtained key regulatory clearances in Europe and is expanding clinical collaborations in North America.
In the Asia-Pacific region, MITRAJECT, based in Singapore, has accelerated its development of compact jet injectors aimed at both vaccine and insulin delivery. Their devices integrate digital feedback for dose confirmation, addressing regulatory focus on traceability and safety. Similarly, INJEX Pharma AG in Germany continues to supply spring-powered jet injectors widely used in diabetes care and dental anesthesia, with updated versions now supporting connectivity to patient monitoring platforms.
Startups are driving innovation, particularly in device miniaturization and integration with digital health. Portal Instruments in Massachusetts has made significant strides in its electronically controlled jet injector, which enables highly controlled, painless administration of biologics. Portal’s device is currently in late-stage clinical evaluation for multiple pharmaceutical partnerships, with commercialization targeted within the next two years.
Other noteworthy players include PharmaJet, which partners with global vaccine manufacturers to deliver World Health Organization-prequalified jet injectors for polio, influenza, and COVID-19 vaccination campaigns. PharmaJet’s Stratis and Tropis devices have seen expanded deployment in both low- and middle-income countries, with ongoing large-scale immunization initiatives in 2025. Meanwhile, Terumo Corporation continues to develop its needle-free injection portfolio, focusing on integrating smart features and expanding applications beyond traditional vaccines.
Looking ahead, the competitive field is expected to intensify as intellectual property portfolios mature and several devices approach full regulatory approval in major markets. Collaborations between device manufacturers and pharmaceutical companies are likely to accelerate, aiming to tailor jet injectors for specific therapeutics and patient populations, while digital health integration will become a key differentiator in usability and data-driven care.
Current Market Size, Segmentation & 2025 Valuations
Jet injection technology is rapidly transforming the landscape of transdermal drug delivery, offering needle-free administration that enhances patient compliance, reduces sharps waste, and mitigates the risk of needle-stick injuries. As of 2025, the global market for jet injectors in medical applications is experiencing robust growth, driven by increasing demand for painless vaccine administration, insulin delivery, and biologics. The current market size is estimated to be in the high hundreds of millions of USD, with strong growth projections through the end of the decade.
Market segmentation within the jet injection sector is primarily based on product type (spring-loaded, gas-powered, battery-powered), application (vaccines, insulin, pain management, dermatology), and end-user (hospitals, clinics, home care). Among these, spring-powered and gas-powered devices dominate due to their established safety profiles and regulatory approvals. For instance, PharmaJet has established a significant footprint with its needle-free injectors adopted for global immunization campaigns, including influenza and COVID-19 vaccines.
Geographically, North America and Europe currently lead the market, thanks to early adoption in public health and the presence of major device manufacturers. However, Asia-Pacific is poised for the fastest growth, propelled by expanding vaccination initiatives and increased healthcare spending. Companies like Injex Pharma AG and Crossject are advancing product lines targeting both developed and emerging markets, underscoring the global nature of this technology’s adoption.
In terms of 2025 valuations, leading manufacturers are reporting substantial increases in order volumes. PharmaJet announced in late 2024 that it had delivered millions of devices for national immunization programs over the past two years. Crossject reported the initiation of commercial-scale production of its ZENEO® single-use, prefilled jet injectors for emergency drugs. The expanding pipeline of drugs being reformulated for jet injection—particularly vaccines, insulin, and emergency medications—further supports optimistic revenue forecasts for the sector.
Looking ahead, the continued expansion of needle-free vaccine delivery, especially in mass immunization and pandemic preparedness, is expected to sustain double-digit market growth rates through at least 2028. Regulatory clearances for new therapeutic applications and increasing investments in R&D by device makers such as Injex Pharma AG suggest that the market will continue to diversify and mature, with broader adoption in both clinical and home settings.
Growth Drivers: Patient Demand, Regulations, and Pharma Partnerships
Jet injection technology for transdermal drug delivery is poised for substantial growth in 2025 and the near future, driven by converging trends in patient preferences, evolving regulatory landscapes, and increasing collaboration between pharmaceutical companies and device manufacturers.
- Patient-Centric Demand: In recent years, patients and healthcare providers have shown a marked preference for needle-free drug delivery systems due to reduced pain, lower risk of needlestick injuries, and improved adherence. Companies such as PharmaJet have reported rising adoption of their jet injectors in vaccination campaigns and routine immunizations in both developed and emerging markets. This trend is expected to accelerate as self-administration and home-based care become more prevalent post-pandemic.
- Regulatory Support and Harmonization: Regulatory bodies, including the U.S. FDA and international agencies, have increasingly recognized jet injector platforms as viable alternatives to traditional needles, with several products receiving clearance or approval for a range of vaccines and biologics. For instance, ZetaJet highlights that their needle-free devices have gained regulatory acceptance for use in multiple countries, paving the way for broader global deployment in 2025 and beyond.
- Pharma Partnerships and Pipeline Expansion: Strategic alliances between jet injection device manufacturers and pharmaceutical firms are accelerating technology development and commercialization. PharmaJet has announced partnerships with vaccine developers for COVID-19, influenza, and other diseases, leveraging rapid fill-and-finish capabilities and device compatibility with emerging biologics. Similarly, Crossject is advancing collaborations for needle-free delivery of emergency and chronic therapies, with several candidates expected to enter late-stage clinical trials or obtain market authorization in the next few years.
- Technological Advancements: Ongoing innovation is yielding more compact, user-friendly, and precise jet injector systems. Companies are integrating features such as dose customization, digital tracking, and enhanced safety mechanisms, as outlined by Crossject in their recent pipeline updates. These improvements are expected to further boost acceptance among healthcare providers and patients alike, expanding the addressable market.
With strong alignment of patient demand, regulatory momentum, and pharma partnerships, jet injection technology is set to play a transformative role in transdermal drug delivery through 2025 and into the next several years.
Emerging Applications: Beyond Vaccines and Insulin
Jet injection technology, traditionally associated with mass vaccination campaigns and insulin administration, is rapidly expanding its scope of applications in 2025 and beyond. Driven by advances in precision engineering and drug formulation, jet injectors are now being explored and deployed for a broader range of therapeutics delivered transdermally, addressing both patient comfort and the growing demand for needle-free delivery systems.
Several companies are pioneering these expansions. PharmaJet, a leading provider of jet injection systems, has recently announced clinical collaborations for delivery of biologics, gene therapies, and monoclonal antibodies. Their latest generation devices are engineered to accommodate a wider viscosity range and larger molecular weight compounds, opening the door to therapies beyond traditional small molecule drugs and vaccines. In 2024, PharmaJet reported promising preliminary results in trials involving intradermal delivery of protein-based therapeutics for infectious diseases and oncology, with multiple phase II studies ongoing in 2025.
Another innovator, INOVIO Pharmaceuticals, is advancing jet injection for DNA-based medicines. Their proprietary device, Cellectra™, is being used in clinical studies for the transdermal administration of DNA plasmids targeting cancers and infectious diseases. In 2025, INOVIO Pharmaceuticals is expected to publish new clinical data on the immunogenicity and tolerability of their needle-free approach, with the company highlighting improved patient compliance and reduced risk of needlestick injuries.
In the dermatology and pain management fields, Crossject has developed ZENEO®, a pre-filled, single-use jet injector platform. In 2024, ZENEO® secured regulatory clearance in Europe for the delivery of methotrexate for rheumatoid arthritis, and the company is actively pursuing indications for migraine and emergency medicine (e.g., epinephrine for anaphylaxis) in 2025. Crossject has also entered strategic partnerships with pharmaceutical manufacturers to co-develop jet-injected formulations of corticosteroids and local anesthetics.
Looking ahead, the outlook for jet injection technology in transdermal drug delivery is robust. As device platforms become more adaptable and regulatory acceptance grows, the next few years will likely see an expansion of approved indications, particularly in biologics, pain management, and emergency therapeutics. The convergence of patient-centric design, digital monitoring, and integration into telehealth workflows is expected to further accelerate adoption, with major players investing in scale-up and decentralized manufacturing models to meet anticipated demand worldwide.
Competitive Analysis: Leading Players and Strategic Moves
The competitive landscape in the jet injection technology sector for transdermal drug delivery is characterized by a dynamic mix of established medical device manufacturers and innovative startups, all striving to address the growing demand for needle-free, patient-friendly solutions. As of 2025, several key players are making strategic moves to secure market share and accelerate technology adoption.
- PharmaJet remains a dominant force, leveraging its FDA-cleared needle-free injectors for vaccines and biologics. In recent years, PharmaJet expanded its partnerships with global vaccine manufacturers, notably collaborating on polio and influenza immunization campaigns. The company’s Stratis and Tropis systems have seen increased procurement by public health organizations, and PharmaJet continues to announce new clinical collaborations targeting intradermal, subcutaneous, and intramuscular delivery.
- Portal Instruments is advancing its digitally controlled jet injection platform aimed at biologics and high-viscosity drugs. In 2024, Portal Instruments extended its partnership with Takeda to develop a needle-free system for biologic therapies. The company is focusing on late-stage clinical validation and regulatory submissions, targeting 2025 for commercial launch in selected markets.
- Crossject (Zeneo® platform) is gaining traction in the European market after obtaining marketing authorizations for several emergency-use medications administered via jet injection. Crossject is scaling up manufacturing capacity and has secured agreements with government agencies for the supply of needle-free auto-injectors for critical care, including epinephrine and midazolam.
- Inovio Pharmaceuticals continues to innovate in the field of electroporation-enhanced jet injectors, particularly for DNA vaccines. Inovio Pharmaceuticals is progressing with late-stage clinical trials and partnerships with government and global health organizations, aiming to address infectious diseases and oncology indications.
- Medical International Technologies (MIT Canada) is expanding its portfolio of spring-powered jet injectors. Medical International Technologies is targeting both human and veterinary applications, with new product launches anticipated in emerging markets.
Strategically, leading players are investing in manufacturing scale-up, regulatory clearances, and forging alliances with pharmaceutical companies to integrate jet injection with new drug formulations. There is a clear focus on addressing large-scale immunization needs, improving patient compliance, and reducing sharps waste. Over the next few years, market outlook remains optimistic, driven by public health initiatives, biologics pipeline growth, and increased acceptance of needle-free solutions.
Regulatory and Safety Landscape: Approvals, Standards, and Challenges
Jet injection technology, which enables needle-free transdermal drug delivery by propelling medications through the skin using high-pressure streams, has seen significant regulatory developments and ongoing safety evaluations through 2025. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global authorities play pivotal roles in shaping the landscape for these devices.
In the United States, jet injectors are classified as Class II medical devices, requiring 510(k) premarket notification for most applications. The FDA has cleared several jet injector systems for drug and vaccine delivery, provided the manufacturers demonstrate substantial equivalence to predicate devices and provide robust data on safety, efficacy, and patient acceptability. For instance, PharmaJet has received multiple FDA clearances for its needle-free injectors used in vaccine delivery, including for seasonal influenza and COVID-19 vaccines. The agency continues to update its guidance on combination products, especially where device-drug integration is involved, necessitating comprehensive risk management and human factors testing.
The EMA and other regulatory authorities in regions such as Asia-Pacific are similarly focused on harmonizing device standards, particularly around sterility, dose accuracy, and prevention of cross-contamination. Notably, the World Health Organization has endorsed certain needle-free injection technologies for global immunization campaigns, citing their potential to improve compliance and reduce sharps-related injuries (World Health Organization).
A key regulatory challenge for jet injectors involves ensuring consistent drug delivery across diverse skin types and settings. Historical concerns about cross-contamination—most notably from earlier multi-use nozzle designs—have prompted strict requirements for single-use components and traceability. Modern systems, such as those from INJEX Pharma and Crossject, incorporate disposable, sterile nozzles to meet these standards and reduce infection risks.
Safety remains a top priority. Regulatory agencies require rigorous clinical and post-market surveillance data to monitor for adverse effects such as skin trauma, local reactions, and rare systemic responses. Manufacturers must also comply with international standards such as ISO 11608 for needle-free injectors, which addresses design, performance, and labeling requirements (International Organization for Standardization).
Looking forward, the regulatory environment for jet injection technologies is expected to evolve in tandem with advances in drug formulations, device connectivity (for data tracking), and personalized medicine. Ongoing collaboration between manufacturers, healthcare providers, and regulators will be critical to address emerging challenges and ensure the safe, effective adoption of jet injectors in mainstream and global health contexts.
Market Forecasts: Growth Projections through 2030
Jet injection technology is witnessing renewed momentum in the transdermal drug delivery sector as demand grows for needle-free, patient-friendly alternatives. In 2025, industry leaders and medical device manufacturers are expanding their portfolios and scaling production to address a global market increasingly focused on vaccination, biologic drug delivery, and chronic disease management. The next five years are projected to see robust growth, driven by innovations in device reliability, user safety, and compatibility with a wider range of pharmaceuticals.
Key manufacturers such as PharmaJet and Crossject are at the forefront of this evolution, with products that have received regulatory clearances in major markets including the United States and Europe. PharmaJet’s needle-free injection systems are now being deployed for intramuscular and subcutaneous injection of vaccines, with ongoing collaborations supporting mass immunization campaigns and expanding applications in seasonal and pandemic preparedness. Crossject is advancing ZENEO® autoinjectors for emergency and routine use, targeting conditions ranging from anaphylaxis to migraine and epileptic seizures.
The market outlook through 2030 is characterized by several drivers:
- Expansion of immunization and biologics programs—needle-free delivery is attractive for reducing needle-stick injuries and improving patient compliance, particularly in pediatric and geriatric populations.
- Regulatory approvals and inclusion in public health procurement channels are accelerating adoption, as evidenced by PharmaJet’s contracts with global health organizations.
- Technological improvements are addressing prior limitations regarding dosing precision, device clogging, and compatibility with viscous or fragile biologics, broadening the range of drugs suitable for jet injection platforms.
By the late 2020s, market penetration is expected to increase significantly across North America, Europe, and Asia-Pacific, with local manufacturers in regions such as India (Hindustan Syringes & Medical Devices) and China also entering the field to meet domestic demand. Strategic partnerships between device developers and pharmaceutical companies are anticipated to accelerate, enabling drug-device co-development and improving market access.
Overall, jet injection technology for transdermal drug delivery is poised for high single-digit to low double-digit annual growth rates through 2030, supported by a pipeline of new device launches, expanding therapeutic indications, and increasing emphasis on needle-free injection in both routine and emergency care.
Future Outlook: Disruptive Technologies and Investment Hotspots
Jet injection technology, which enables needle-free transdermal drug delivery through high-velocity liquid streams, is poised for significant evolution and commercial expansion in 2025 and the near future. This technology addresses the perennial challenges of injection pain, risk of needlestick injuries, and medical waste, making it a disruptive alternative particularly in mass vaccination, chronic disease management, and biologics administration.
Several major manufacturers are advancing next-generation jet injectors. Philips has announced continued refinement of its jet injector portfolio, aiming to improve dosing accuracy and patient comfort through digital pressure control. Meanwhile, Portal Instruments is progressing with its digitally connected jet injection system, designed for the self-administration of biologics. This device, currently in advanced clinical testing, is expected to move toward broader regulatory submissions and commercialization in late 2025.
Market expansion is also driven by partnerships between device innovators and pharmaceutical companies. For example, Novartis has partnered with Portal Instruments to develop needle-free delivery of biologic drugs for chronic conditions, with pilot programs and real-world data collection scheduled to accelerate through 2025. Similarly, BD (Becton, Dickinson and Company) is investing in the development of advanced jet injection platforms to complement its portfolio of drug delivery solutions.
Key regulatory and infrastructure developments are expected to further propel adoption. The U.S. FDA and European Medicines Agency have both issued updated guidance in 2024 to streamline the pathway for combination products that include needle-free injectors, potentially shortening the time to market for new therapies. In parallel, global vaccination initiatives in response to emerging infectious diseases are increasingly evaluating jet injection for mass immunization campaigns, due to its efficiency and reduced logistical requirements.
Looking ahead, investment hotspots are emerging around miniaturized, digitally enabled jet injectors for home use, as well as high-throughput devices suitable for public health emergencies. Companies such as INJEX Pharma AG are scaling up manufacturing capacity to meet anticipated demand. The sector is also seeing increased venture capital and strategic investment, reflecting confidence in jet injection’s potential to disrupt the $30+ billion injectable drug market.
Through 2025 and beyond, the convergence of digital health, patient-centric design, and supportive regulatory frameworks is expected to drive rapid adoption and innovation in jet injection technology, positioning it as a transformative force in transdermal drug delivery.
Sources & References
- Portal Instruments
- Inovio Pharmaceuticals
- Crossject
- Philips
- Terumo Corporation
- ZetaJet
- INOVIO Pharmaceuticals
- Medical International Technologies
- World Health Organization
- International Organization for Standardization
- Novartis